Syntax Bio Announces Expanded Series A and Leadership Appointments
AI Briefing
- * Syntax Bio expands Series A funding to $14.4 million, reaching total funding of over $25 million.
- * New appointments made to executive leadership, board of directors, and scientific advisory board.
- * Expansion builds on support from major investors including Astellas Venture Management and Illumina Ventures.
Source Summary
CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s Series A to $14.4 million and total funding to over $25 million. The expanded round builds on support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansu
Advertisement